CALCA and migraine disorder: Calcitonin gene-related peptide was overtaking many a neuropeptide in its path to clinical exploitation, given that only some 20 years after its discovery (Rosenfeld et al., 1983) a landmark paper (Olesen et al., 2004) provided clinical proof of the concept that a small molecule antagonist of CGRP (code name BIBN4096BS, later given the international non-proprietary name olcegepant) is able to prevent and treat migraine.